



Press release
Lund, Sweden 2018-03-16

CLS and Toronto General Hospital, Canada, carry out clinical study regarding MRI guided FLA treatment of prostate cancer

Clinical Laserthermia Systems AB's (publ) TRANBERG® | Thermal Therapy System and single use accessories will be used in a clinical study regarding MRI guided FLA treatment of prostate cancer, initiated by Toronto General Hospital in Toronto, Canada. The study will include 25 patients and has obtained ethical approval as well as approval from Health Canada. The study will begin in April 2018 and go on for 24 months. The purpose of the study is to evaluate safety and efficacy in treatment of prostate cancer with MRI guided focal laser ablation.

- I am very pleased that Toronto General Hospital has chosen our products for its clinical study. We will in a systematic way get access to important data on how our products perform when used in MRI guided focal laser ablation treatment. The study includes men with early stage prostate cancer, who have not undergone radiation or hormone treatment, said Lars-Erik Eriksson, CEO of CLS.

The clinical study is initiated by Toronto General Hospital. CLS will lend the TRANBERG-system to the hospital and stand the costs for the single use products used with each treatment. In conjunction with the start of the study at Toronto General Hospital, CLS has decided to close a clinical study, regarding imILT® treatment of prostate cancer, that the company has carried out at Skånes Universitetssjukhus in Malmö, Sweden, and where no treatments have been possible to execute due to lack of resources.

- For prostate cancer we will now focus our resources on FLA treatment and continue to establish the TRANBERG system for this method, where the U.S. and Canada are large markets. This does not exclude that imILT can be interesting for this type of cancer further on, but we see a value in building on our ongoing activities in the U.S. and take the opportunity to establish the TRANBERG system for FLA treatment of early stage prostate cancer, said Lars-Erik Eriksson.

Toronto General Hospital will register the clinical study on www.clinicaltrials.gov

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Company Contact:

Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)

Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®/Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se